Adjuvant therapy for renal-cell carcinoma: settled for now

Lancet. 2016 May 14;387(10032):1973-4. doi: 10.1016/S0140-6736(16)00653-X. Epub 2016 Mar 9.

Authors

Stefan Duensing¹, Markus Hohenfellner²

Affiliations

¹ Section of Molecular Urooncology, University of Heidelberg, Medical Faculty Heidelberg, D-69120 Heidelberg, Germany; Department of Urology, University of Heidelberg, Medical Faculty Heidelberg, D-69120 Heidelberg, Germany. Electronic address: [email protected].
² Department of Urology, University of Heidelberg, Medical Faculty Heidelberg, D-69120 Heidelberg, Germany.

PMID: 26969091
DOI: 10.1016/S0140-6736(16)00653-X

No abstract available

Publication types

Comment

MeSH terms

Antineoplastic Agents / administration & dosage*
Carcinoma, Renal Cell / drug therapy*
Female
Humans
Indoles / administration & dosage*
Kidney Neoplasms / drug therapy*
Male
Niacinamide / analogs & derivatives*
Phenylurea Compounds / administration & dosage*
Pyrroles / administration & dosage*

Substances

Antineoplastic Agents
Indoles
Phenylurea Compounds
Pyrroles
Niacinamide